A doctor is online now – good chance of an appointment today
Home · Blog · Wegovy or Mounjaro not working

How big is the risk that Wegovy or Mounjaro won't work?

When you start on Wegovy (semaglutide) or Mounjaro (tirzepatide), it is natural to ask: what if the medicine does not work for me? The studies give a reassuring answer, because the vast majority get a clear effect.

Adam Omari Licensed doctor and medical director, Recepta

Published 15 November 2026 · Reading time 3 min.

Short answer

The risk that Wegovy or Mounjaro will not work is small. In the large studies, about 6 in 7 lost at least 5% of their weight on Wegovy, and 85 to 91% did so on Mounjaro. About 1 in 7 lost less than 5%. In everyday practice the figures are lower, mostly because many people are on a low dose or stop early.

How many people get an effect from Wegovy and Mounjaro?

The vast majority get an effect from Wegovy and Mounjaro: in the studies, between 85% and 91% lost at least 5% of their weight.

In the STEP 1 study, adults with overweight or obesity without diabetes were given Wegovy 2.4 mg for 68 weeks along with advice on diet and exercise. 86.4% lost at least 5% of their weight, compared with 31.5% on placebo (an inactive dummy treatment). 69.1% lost at least 10%, and 50.5% lost at least 15%.[1]

In the 72-week SURMOUNT-1 study, Mounjaro gave a weight loss of at least 5% in 85% of people on 5 mg, 89% on 10 mg and 91% on 15 mg, compared with 35% on placebo.[2]

Share who lost at least 5% of their weight
Wegovy 2.4 mgSTEP 1, 68 weeks
86.4%
Mounjaro 5 mgSURMOUNT-1, 72 weeks
85%
Mounjaro 10 mg
89%
Mounjaro 15 mg
91%
Placebo in STEP 1inactive dummy treatment
31.5%
Placebo in SURMOUNT-1
35%

The two studies had different participants and durations, so the figures for Wegovy and Mounjaro cannot be compared directly.[1][2]

Why do some people lose less weight outside the studies?

Some people lose less weight outside the studies because more of them stop treatment early or stay on a low dose.

Researchers from Cleveland Clinic in the USA followed 7,881 patients on semaglutide or tirzepatide in everyday practice. The average weight loss after one year was 8.7%. Those who stopped early lost 3.6% on average, while those who continued lost 11.9%.[3]

80.8% were on a low maintenance dose, meaning the fixed dose after dose escalation. The researchers themselves put the lower weight loss down to more people stopping and lower doses than in the studies. This suggests that a steady course of treatment with the right dose and good follow-up matters a lot for the result.[3]

What does the doctor do if your weight is not moving?

If your weight is not moving on Wegovy or Mounjaro, the doctor assesses whether the treatment needs more time, a higher dose or a switch to another medicine.

Wegovy is stepped up over 16 weeks to 2.4 mg, so the full effect only comes after a few months. In the EU, a higher Wegovy dose of 7.2 mg is also approved for adults with a BMI (the ratio between weight and height) of 30 or above. The doctor can also consider the other medicine.[4]

Changes to dose or medicine are always for the doctor to assess, so you should not turn the dose up or down yourself. At Recepta you start with a free doctor consultation by video or phone, and the doctor follows up every 4 weeks.

Read also: How do you know if Wegovy is working for you? · Wegovy or Mounjaro: which is better?

Questions and answers about the effect of Wegovy and Mounjaro

How many people lose at least 10% of their weight on Wegovy?
In the STEP 1 study, 69.1% of participants on Wegovy lost at least 10% of their weight over 68 weeks, and 86.4% lost at least 5%.
Does a slow start mean that Wegovy is not working?
No, a slow start does not mean that Wegovy is not working. Wegovy is stepped up over 16 weeks to 2.4 mg, so the full effect only comes after a few months.
How does the doctor at Recepta follow up on the treatment?
At Recepta the course of treatment starts with a free doctor consultation by video or phone, and after that the doctor follows up every 4 weeks and adjusts the treatment as needed.

Sources

  1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine 2021;384(11):989-1002. doi.org
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine 2022;387(3):205-216. doi.org
  3. Gasoyan H, Butsch WS, Schulte R, et al. Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status. Obesity 2025;33(9):1657-1667. doi.org
  4. European Medicines Agency (EMA): Summary of product characteristics for Wegovy (semaglutide), section 4.2 on dosing. ema.europa.eu

Would you like to know if medical weight loss is right for you?

A licensed Danish doctor assesses which treatment suits you. The consultation is free, and you only pay once the doctor has approved treatment.

Prescription medicine is only prescribed after the doctor's individual assessment.

This post is general information and does not replace a medical assessment. Never stop or switch medication on your own. Recepta is a doctor's clinic that treats patients with this type of medication, among others. If you have questions about a treatment you are already on, write to your doctor on My page. If you have acute symptoms, contact your own doctor, the out-of-hours doctor service (lægevagten) or call 112.